Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up duration of study (up to 11 weeks)
Summary
This trial tests a new drug called BGB-23339 in healthy Japanese and Caucasian people. It aims to find out if there are any differences in safety, tolerability, and how the body processes the drug between these two groups.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ duration of study (up to 11 weeks)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of study (up to 11 weeks)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with Adverse Events (AEs)
Trial Design
2Treatment groups
Experimental Treatment
Group I: Part B: Caucasian cohortExperimental Treatment2 Interventions
One dose level of either BGB-23339 or placebo based on data collected in Part A.
Group II: Part A: Japanese cohortExperimental Treatment2 Interventions
Three ascending dose levels of either BGB-23339 or placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BGB-23339
2021
Completed Phase 1
~100
Placebo
1995
Completed Phase 3
~2670
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
BeiGeneLead Sponsor
197 Previous Clinical Trials
30,736 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Share this study with friends
Copy Link
Messenger